Full Professor
Strategic program(s):
Biography
Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002, as clinical microbiologist in 2008 and as Epidemiologist (B) in 2025, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.
He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)
Coordinator of the H2020-funded projects ECRAID-Base (March 2021-), ECRAID-Prime (Dec 2021-) and Chief Executive Officer of the ECRAID foundation (Jan 2022-)
Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)
Research aim
To improve prevention, diagnosis and treatment of infectious diseases and to establish an international research infrastructure for a rapid scientific response in the face of a new infectious disease threat.
Go to groupResearch aim
We design and conduct clinical epidemiological research focused on risk stratification, early diagnosis, and novel treatment of critically ill patients with severe infections.
Go to groupHe is a VICI laureate (2006) from the Dutch Science Association, Principal Investigator of the CAPiTA study, coordinator of the EU-funded project R-GNOSIS, scientific coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET and PrimaVeRa. He is member of the International Trial Steering Committee of the REMAP-CAP study and the SNAP-study, and coordinator of ECRAID-Base and ECRAID-Prime.
In 2015 he received the ESCMID 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases.
In 2017 he received a honorary fellowship of the Royal College of Physicians of Ireland, and was awarded the ESCMID fellowship.
In 2021 he was elected member of the Koninklijke Nederlandse Academi voor Wetenschappen.
CEO - Clinical trials - Ecraid
Consultancy, assisteren bij het identificeren van geschikte studie lokaties voor fase3 studie - Werkzaamheden in kader van mijn rol als CEO Ecraid - Janssen Research
Via Ecraid, identificeren van geschikte klinieken voor deelname aan wetenschappelijk onderzoek - CEO van Ecraid - Spherecytes
Wetenschappelijk advies - Expertisegebied - Pherecydes Pharma
Scientific Advisor Ensovibep - Expertise - Novartis
Member Scientific Advisory Board - Scientific evaluation of GRADP-funded research projects - GARDP
Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal vaccination. - expertise - Sanofi Pasteur
Chair of international study steering committee E.mbrace study - Expertise area - Janssen Vaccines and Prevention BV
